Galleri Trial Misses Main Goal in 142,000 NHS Patients as Stage 4 Cancers Fall 14%
Updated
Updated · The Guardian · May 30
Galleri Trial Misses Main Goal in 142,000 NHS Patients as Stage 4 Cancers Fall 14%
5 articles · Updated · The Guardian · May 30
Data from the first randomized controlled trial of a multi-cancer blood test showed Galleri did not significantly cut stage 3-4 diagnoses when added to standard NHS screening in 142,942 symptom-free adults.
The study tested annual blood draws over three years in people aged 50 to 77, with half receiving Galleri analysis and follow-up diagnostics after positive results.
Grail pointed to a 14% drop in stage 4 cancers alone as an encouraging secondary signal, but ASCO and outside experts said the trial still failed its predefined primary endpoint.
Researchers and NHS England said fuller data and mortality results due in the next couple of years will determine whether the test has any role in population-wide screening.
If the Galleri cancer test failed its trial, why do some experts still call it a genuine hope?
With its main goal unmet, how could this test qualify for the new US Medicare coverage law?